CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More

Frontiers in Cell and Developmental Biology

Xuelei Ma¹  Zhiyao He²  Qizhi Ma³  Xuejin Ou³  Wei Yin⁴ 

[1] Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China;Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China;Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China;West China School of Medicine, Sichuan University, Chengdu, China;

关键词: CRISPR/Cas9;    immunotherapy;    TCR-T;    tumor-infiltrating lymphocytes;    CAR-T;   

DOI  :  10.3389/fcell.2021.674467

来源: DOAJ

【 摘 要 】

In recent years, immunotherapy has showed fantastic promise in pioneering and accelerating the field of cancer therapy and embraces unprecedented breakthroughs in clinical practice. The clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (CRISPR-Cas9) system, as a versatile gene-editing technology, lays a robust foundation to efficiently innovate cancer research and cancer therapy. Here, we summarize recent approaches based on CRISPR/Cas9 system for construction of chimeric antigen receptor T (CAR-T) cells and T cell receptor T (TCR-T) cells. Besides, we review the applications of CRISPR/Cas9 in inhibiting immune checkpoint signaling pathways and highlight the feasibility of CRISPR/Cas9 based engineering strategies to screen novel cancer immunotherapy targets. Conclusively, we discuss the perspectives, potential challenges and possible solutions in this vivid growing field.

【 授权许可】

Unknown